Description

Specifications

• Form: White lyophilized powder
• Standard vial size: research-grade, typically supplied in mg quantities
• Purity: ≥99% (HPLC & Mass Spec verified)
• Class: Single-chain relaxin-2 mimetic peptide
• Storage: Store lyophilized powder at -20°C; refrigerate at 2–8°C once reconstituted

Overview

B7-33 is an engineered single-chain peptide designed to selectively activate a subset of relaxin-2 receptor (RXFP1) signaling pathways, isolating the anti-fibrotic activity of relaxin from its other systemic effects.

Mechanism & Research Findings

Native relaxin-2 activates RXFP1 through both cAMP and ERK1/2/nitric-oxide signaling arms. Research indicates B7-33 selectively engages the ERK1/2 pathway associated with anti-fibrotic activity while largely sparing the cAMP-driven arm, allowing investigators to isolate anti-fibrotic signaling from relaxin’s broader cardiovascular and renal effects. This selectivity has made B7-33 a compound of interest in cardiac, renal, and hepatic fibrosis research models.

Research Applications

• RXFP1 / relaxin receptor pathway-selectivity research
• Cardiac and renal fibrosis models
• Comparative studies vs. native relaxin-2 signaling

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.